Devax
Founded Year
1999Stage
Acquired | AcquiredTotal Raised
$15.19MValuation
$0000About Devax
Devax is a medical device company engaged in the development of a proprietary drug eluting stent system that aims to provide a clinical solution to treat coronary, carotid and peripheral vascular bifurcation lesions.
Missing: Devax's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Devax's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Devax Patents
Devax has filed 2 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/24/2006 | 3/30/2010 | Implants (medicine), Angiology, Bifurcation theory, Vascular surgery, Interventional cardiology | Grant |
Application Date | 10/24/2006 |
|---|---|
Grant Date | 3/30/2010 |
Title | |
Related Topics | Implants (medicine), Angiology, Bifurcation theory, Vascular surgery, Interventional cardiology |
Status | Grant |
Devax Frequently Asked Questions (FAQ)
When was Devax founded?
Devax was founded in 1999.
Where is Devax's headquarters?
Devax's headquarters is located at 13700 Alton Parkway, Irvine.
What is Devax's latest funding round?
Devax's latest funding round is Acquired.
How much did Devax raise?
Devax raised a total of $15.19M.
Who are the investors of Devax?
Investors of Devax include Biosensors International, Rock Creek Capital, MedFocus Fund, International Biomedicine Management Partners, Private Life Biomed AG and 10 more.
Who are Devax's competitors?
Competitors of Devax include Epitomee Medical, Svelte Medical Systems, Tryton Medical, Vascular Pathways, ArraVasc and 16 more.
Compare Devax to Competitors
TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
SquareOne is developing a stent delivery system.
Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.
Stent systems develops angioplasty catheters and guidewires, and related interventional products
Endothelix, Inc. is a cardiovascular device company focused on addressing inaccurate individualized prediction of cardiovascular risk and inadequate monitoring of the vascular response to treatments.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.